Dr.Wenchang Guo’s Curriculum Vitae
AP/CP and GI/Liver Pathologist

GENERAL INFORMATION
Wenchang Guo, MD, PhD, FACP Clinical Instructor of Pathology GI/Liver Pathology Fellow
University of California Irvine (UCI) Medical Center Department of Pathology and Laboratory Medicine 101 The City Dr S, Orange, CA 92868
E-mail: wenchangguo@yahoo.com wenchang@uci.edu
Phone: 415-680-5220
Citizenship: US citizen

FELLOWSHIPS AND RESIDENCY
2019-2020 Clinical Instructor (GI/Liver Pathology Fellowship), University of California Irvine Medical Center, Orange, CA
2018-2019 Surgical Pathology Fellowship, University of Southern California/LAC+USC Medical Center, Los Angeles, CA
2014-2018 Anatomic and Clinical Pathology (AP/CP) Residency, University of Southern California/LAC+USC Medical Center, Los Angeles, CA

PROCEDURAL EXPERIENCE
Residency:
Surgical Pathology specimens grossed and signed out: around 5000 Frozen sections performed and diagnosed: 357
FNA biopsies performed (including U/S-guided FNA): 53 Autopsies: 54

Fellowship:
Surgical pathology fellowship at USC: Frozen sections performed and diagnosed: 408
GI/Liver pathology fellowship at UCI: All liver biopsies, GI frozen sections and GI tumor boards, and
independent frozen and sign-out responsibilities

BOARD CERTIFICATION
American Board of Pathology, Anatomic and Clinical Pathology 2018

MEDICAL LICENSE
California Medical License, A146608, Active

PROFESSIONAL MEMBERSHIPS
CAP (Collage of American Pathologists), 2019-present
ASCP (American Society for Clinical Pathology), 2019-present CAPA (Chinese American Pathologists Association), 2019-present

LASOP (Los Angeles Society of Pathologists, Inc.), 2015-present

ONGOING PROJECTS AND INTERESTING CASE REPORTS
1. INSM1 in neuroendocrine cell tumor. Dr. Wenchang Guo, Dr. Xiaodong Li, Dr. Vishal Chandan
2. GATA3 in gallbladder carcinoma. Dr. Wenchang Guo, Dr. Xiaodong Li, Dr. Vishal Chandan
3. PD-L1 in pancreatic solid pseudopapillary neoplasm. Dr. Wenchang Guo, Dr. Xiaodong Li, Dr. Vishal Chandan
4. MSI in colon cancer. Dr. Whayoung Lee, Dr. Wenchang Guo, Dr. Xiaodong Li, Dr. Vishal Chandan
5. Fasciola Hepatica infection mimicking cholangiocarcinoma, a case report. Dr. Wenchang Guo, Dr. Butler-Wu, Dr. Saber, Dr. Naritoku
6. Follicular dendritic cell sarcoma, a case report. Dr. Wenchang Guo, Dr. Vergara-Lluri

EDUCATION
2002-2007 Ph.D., Toxicology, University of Colorado, Denver, CO
1992-1997 M.D., Sun Yat-Sen University of Medical Sciences, Guangzhou, China

RESEARCH EXPERIENCE
2013-2014 Assistant Project Scientist, Department of Biochemistry and Molecular Medicine, UC Davis, CA Supervisor: Kit S. Lam, MD, Ph.D. Professor/Chair; Hsing-Jien Kung, Ph.D. Professor
2008-2013 Postdoctoral Scholar, UC Davis Comprehensive Cancer Center. Sacramento, CA Supervisor: Kit S. Lam, MD, Ph.D. Professor/Chair; Hsing-Jien Kung, Ph.D. Professor
2007-2008 Postdoctoral Research Fellow, University of Colorado Denver, School of pharmacy, CO Supervisor: David Ross, Ph.D. Professor/Chair

TEACHING EXPERIENCE
2002-2003 Teaching Assistant, University of Colorado Denver, School of Pharmacy
1997-2002 Instructor, Department of Clinical Education, Sun Yat-Sen University of Medical Sciences

PATENTS
1. David Ross, Wenchang Guo, David Siegel, S.P. Christopher Mcerlean, J. Christopher Moody. Hsp90 inhibitors with modified toxicity. US Patent number: US8551964B2. 2008
2. David Ross, David Siegel, Philip Reigan, Wenchang Guo, Daniel Gustafson. Hsp90 inhibitors, methods of making and uses therefore. US Patent number: US7608611B2. 2005

AWARDS
2009-2011 Etk inhibitors, Autophagy and Apoptosis in prostate cancer cells. DOD postdoctoral training award. W81XWH-09-1-0235. $101,205. Role: PI (principal investigator)

PEER-REVEWED PUBLICATIONS
1. Itzel Bustos-Villalobos, Jennifer Williams Bergstrom, Nathan E. Haigh, Jesus I. Luna, Anupam Mitra, Alina I. Marusina, Alexander A. Merleev, Elizabeth A. Wang, Andrea Sukhov, Hawa Sultani, Ruiwu Liu, Gaurav Bhardwaj, Wenchang Guo, Hsing-Jien Kung, Kit S. Lam, Emanual Maverakis. ITK inhibition for the targeted treatment of CTCL. J Dermatol Sci. 87(1):88-91. 2017

2. Tzu-yin Lin, Wenchang Guo, Qilai Long, Aihong Ma, Qiangqiang Liu, Hongyong Zhang, Yee Huang, Siddarth Chandrasekaran, Chongxian Pan, Kit S. Lam, and Yuanpei Li. HSP90 Inhibitor Encapsulated
Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics. 2016 Jun 7;6(9):1324-35. (Co-first author)
3. Yuanpei Li, Tzu-yin Lin, Yan Luo, Qiangqiang Liu, Wenwu Xiao, Wenchang Guo, Diana Lac, Hongyong Zhang, Caihong Feng, Sebastian Wachsmann-Hogiu, Jeffrey H. Walton, Simon R. Cherry, Douglas J. Rowland, David Kukis, Chongxian Pan, and Kit S. Lam. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nature Communications. 5:4712. 2014
4. Wenchang Guo, Ruiwu Liu, Gaurav Bhardwaj, Joy Yang, Austin Changou, Ai-Hong Ma, Anisha Mazloom, Sree Chintapalli, Kai Xiao, Wenwu Xiao, Kumaresan Pappanaicken, Eduardo Sanchez, Chi-Tai Yeh, Christopher P. Evans, Randen Patterson, Kit S. Lam, and Hsing-Jien Kung. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death & Disease. 5, e1409. 2014
5. Wenchang Guo, Ruiwu Liu, Gaurav Bhardwaj, Ai-Hong Ma, Chun Changou, Joy C. Yang, Yuanpei Li, Caihong Fen, Yan Luo, Anisha Mazloom, Eduardo Sanchez, Yan Wang, Wenzhe Huang, Randen Patterson, Christopher
P. Evans, Kit S. Lam, and Hsing-Jien Kung. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. Plos One. 8(8): e70910. 2013
6. Wenchang Guo, Ruiwu Liu, Yoko Ono, Aihong Ma, Anthony Martinez, Eduardo Sanchez, Yan Wang, Wenzhe Huang, Anisha Mazloom, Jixian Li, Jinying Ning, Emanual Maverakis, Kit S. Lam, and Hsing-Jien Kung. Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Molecular Pharmacology. 82(5):938-47. 2012
7. Philip Reigan, David Siegel, Wenchang Guo, David Ross. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Molecular Pharmacology. 79(5):823-32. 2011
8. Wenchang Guo, Philip Reigan, David Siegel, David Ross. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metabolism and Disposition. 36(10):2050-7. 2008
9. Wenchang Guo, David Siegel, David Ross. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. Journal of Pharmaceutical Sciences. 97(12):5147-57. 2008
10. Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, and David Ross. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 (NQO1) to more potent heat shock protein 90 (Hsp90) inhibitors, the hydroquinone ansamycins. Molecular Pharmacology. 70(4): 1194-203. 2006
11. Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, and David Ross. Formation of 17-Allyamino-Demethoxygeldanamycin (17-AAG) Hydroquinone by NAD(P)H:Quinone Oxidoreductase 1: Role of 17-AAG Hydroquinone in Heat Shock Protein 90 Inhibition. Cancer Research. 65(21): 1006-15. 2005
12. Wenchang Guo, Churong Yan, Wenzhen Zhang. The problems and skills for the clinical internship of medical students. Supplement to The Journal of Sun Yat-Sen University. 2002

BOOK CHAPTER

1. Ling-Yu Wang, Wenchang Guo, Kevin Kim, Mamata Pochampalli, Chiu-Lien Hung, Yoshihiro Izumiya, and Hsing-Jien Kung. Histone Demethylases in Prostate Cancer. Chapter 15 of book Nuclear Signaling Pathways and Targeting Transcription in Cancer. ISBN 978-1-4614-8038-9. 2013

CONFERENCE PRESENTATIONS
1. Wenchang Guo, Ali Nae, Henry Tran, Jared Shows and David M. Parham. Histological, immunohistochemical and Molecular genetic analysis of Ectomesenchymoma. USC Pathology Department Retreat. 2018
2. Wenchang Guo, Ruiwu Liu, Aihong Ma, Wenzhe Huang, Kit S. Lam, Hsing-Jien Kung. Etk inhibitors, Autophagy and Apoptosis in prostate cancer cells. IMPCT meeting. Orlando, FL. 2011
3. Wenchang Guo, Ruiwu Liu, Aihong Ma, Kit S. Lam, Hsing-Jien Kung. Identification of a novel class of Itk inhibitors selective for Itk and T cell leukemias. UC Davis Cancer Center Symposium. Sacramento, CA. 2009
4. Wenchang Guo, David Siegel, Philip Reigan, Joseph Zirrolli, Daniel Gustafson, and David Ross. Reduction of a series of benzoquinone ansamycin Hso90 inhibitors by one and two electron reductases, and their interaction with reduced glutathione. 98th AACR annual meeting. Los Angeles, CA. 2007
5. Wenchang Guo, David Siegel, Philip Reigan and David Ross. Stability of Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. 98th AACR annual meeting. Los Angeles, CA. 2007
6. Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, and David Ross. Hydroquinone ansamycins are more potent Hsp90 inhibitors. Biowest 2006. Denver, CO. 2006
7. Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, and David Ross. Reduction of benzoquinone ansamycin Hsp90 inhibitors by NQO1 generates hydroquinone ansamycins which are more potent Hsp90 inhibitors. 97th AACR annual meeting. Washington D. C. 2006
8. Wenchang Guo, Philip Reigan, David Siegel, Joseph Zirrolli, Daniel Gustafson, and David Ross. A potential role for NAD(P)H:quinone oxidoreductase 1 (NQO1) in the mechanism of action of the HSP90 inhibitors geldanamycin and 17AAG. . 96th AACR annual meeting. Anaheim CA. 2005
9. Wenchang Guo, David Siegel, Joseph Zirrolli, Daniel Gustafson and David Ross. The Role of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) in the Metabolism of the Hsp90 Inhibitors Geldanamycin, 17AAG and 17AG. AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Geneva, Switzerland. 2004
10. Wenchang Guo, David Siegel, Joseph Zirrolli, Daniel Gustafson and David Ross. The Role of NAD(P)H:Quinone Oxidoreductase 1 (NQO1) in Geldanamycin, 17AAG and 17AG metabolism. Annual meeting of mountain west society of toxicology. Park City, UT. 2004

HOBBIES AND INTERESTS
Spending time with family, running, biking, hiking, fitness

LANGUAGES
English, Mandarin

REFERENCES

Vishal S. Chandan, MD
Professor of Pathology
Director, Gastrointestinal/Liver Pathology Fellowship University of California Irvine (UCI) Medical Center
Department of Pathology and Laboratory Medicine, Room 3624 101 The City Dr S, Orange, CA 92868
E-mail: vchandan@uci.edu Phone: 714-456-7792

Beverly Y. Wang, MD
Professor of Pathology
Vice Chair of Pathology, Chief of Anatomic Pathology University of California Irvine (UCI) Medical Center
Department of Pathology and Laboratory Medicine, Room 3621 101 The City Dr S, Orange, CA 92868
E-mail: bevwang@uci.edu Phone: 714-456-8920

Yanling Ma, MD
Professor of Pathology Director of Surgical Pathology LAC+USC Medical Center
Department of Pathology and Laboratory Medicine 1200 North State Street, Los Angeles, CA 90033
E-mail: yanlingm@usc.edu Phone: 323-409-1370

Wesley Y. Naritoku, MD, PhD
Professor of Pathology
AP/CP Residency and Core Program Director LAC+USC Medical Center
Department of Pathology and Laboratory Medicine 1200 North State Street, Los Angeles, CA 90033
E-mail: naritoku@usc.edu Phone: 323-409-4698

< Back to Pathologists